[Anti-tumor immunotherapy based on dendritic cells].

Area of Science:

• Immunology
• Oncology
• Cell Therapy

Background:

• Dendritic cells (DC) loaded with tumor-associated antigens (TAA) represent a promising cancer immunotherapy strategy.
• Pilot clinical trials were conducted to evaluate the safety and immunogenicity of TAA-loaded autologous DC.

Purpose of the Study:

• To assess the safety and immunological effects of TAA-loaded autologous DC in cancer patients.
• To investigate the impact of subcutaneous (s.c.) IL-2 administration on immune responses.

Main Methods:

• Three pilot clinical trials were performed using TAA-loaded autologous DC.
• Immunological endpoints were measured, including TAA-specific IFN-gamma and IL-5 production.
• Clinical responses were monitored in patients receiving the therapy.

Main Results:

• The TAA-loaded DC approach was found to be safe.
• Potent, but transient, TAA-specific IFN-gamma responses were induced.
• Subcutaneous IL-2 administration led to long-lasting TAA-specific IL-5 production.
• Approximately one-third of patients showed clinical responses.

Conclusions:

• TAA-loaded autologous DC immunotherapy is safe and can elicit TAA-specific immune responses.
• Combining DC therapy with s.c. IL-2 may enhance immune response duration and quality.
• Future strategies involve novel DC types and tumor cell-DC hybrids for improved efficacy.